Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. These engineered cells not only destroyed the infected cells, they persisted for more than two years, suggesting the potential to create long-term immunity from the virus that causes AIDS.
Antiviral drugs can suppress the amount of HIV in the body to nearly undetectable levels, but only an effective immune response can eradicate the virus. Researchers have been seeking a way to improve the body’s ability to combat the virus by engineering blood-forming stem cells to specifically target and kill HIV-infected cells for the life of the individual. Although chimeric antigen receptor (CAR) T-cells have emerged as a powerful immunotherapy for various forms of cancer – and show promise in treating HIV-1 infection – the therapy may not impart long-lasting immunity. Researchers, physicians and patients need T cell-based products that can respond to malignant or infected cells that may reappear months or years after treatment.
Because HIV uses CD4 to infect cells, the researchers used a CAR molecule that hijacks the essential interaction between HIV and the cell surface molecule CD4 to make stem cell-derived T-cells target infected cells. When the CD4 on the CAR molecule binds to HIV, other regions of the CAR molecule signal the cell to become activated and kill the HIV infected cell. The researchers found that, in test animals, modification of the blood-forming stem cells resulted in more than two years of stable production of CAR-expressing cells without any adverse effects. In addition, these cells were widely distributed throughout the lymphoid tissues and gastrointestinal tract, which are major anatomic sites for HIV replication and persistence in infected people. Most important, engineered CAR T-cells showed efficacy in attacking and killing HIV-infected cells.
These findings are the first to show that blood-forming stem cells can be modified with a CAR therapy that can safely engraft in the bone marrow, mature and become functional immune cells throughout the body. This could lead to the development of an approach allowing for safe, lifelong immunity to HIV. Such an approach is likely to work best when performed in combination with other treatment strategies, such as antiretroviral therapy. Researchers hope that this type of therapy could reduce infected individuals’ dependence on antiviral medications, lower the cost of therapy, and permit the possible eradication of HIV from its hiding places in the body. The approach also has potential against other infections or malignancies.
The Latest on: HIV gene therapy
- Global Gene Therapy Market is forecast to hit $363 million by 2022on February 27, 2020 at 4:25 am
Strengthened by recent approvals of Kymriah, Yescarta and Luxturna in the US, and a committed European, Japanese and Chinese environment, gene therapy is set to become a significant player in the ...
- Gilead loses two more patent challenges on HIV pill, setting up courtroom fight in Delawareon February 21, 2020 at 8:33 am
Gilead sustained two more losses in their efforts to rid themselves of an activist-backed patent lawsuit from the US government over a best-selling HIV pill. Urged on by activists seeking to divert ..
- Global Gene Therapy Market 2020 Share, Size, Future Demand, Global Research, Top Leading player, Emerging Trends, Region by Forecast to 2025on February 17, 2020 at 8:02 am
Global Gene Therapy Market" has covered and analyzed the potential of Worldwide Gene Therapy Industry and provides statistics and information on market dynamics, growth factors, key challenges, major ...
- Retroviral Vectors for Gene Therapyon February 11, 2020 at 4:00 pm
The complex retroviruses, such as HIV, encode additional trans-regulating ... lentiviruses and foamy viruses have been used for gene-therapy approaches. Since studies with foamy viruses are ...
- HIV used in gene therapy to fix ‘bubble boy’ diseaseon February 3, 2020 at 4:00 pm
Now eight babies with “bubble boy disease” have had it fixed by a gene therapy made from one of the immune system’s worst enemies — HIV, the virus that causes AIDS. A study out Wednesday ...
- Dr. Hans-Peter Kiem speaks about HIV and making gene therapy more accessible at TEDxSeattleon January 27, 2020 at 3:16 pm
and researchers are studying whether gene therapy could also cure HIV. However, current technologies are expensive, risky and require high-tech facilities, making them inaccessible to many of the 38 ...
- CytoDyn to showcase leronlimab's HIV-prevention potential at Boston medical conferenceon January 27, 2020 at 5:57 am
a professor at the Vaccine and Gene Therapy Institute at the Oregon Health & Science University and a senior adviser to CytoDyn, will lead the presentation. “The acceptance of Dr. Sacha’s ...
- Coming soon: A cure for HIVon January 24, 2020 at 4:00 pm
Washington D.C. [USA], Apr 11 : In what may soon pave the way for an HIV cure, a team of scientists ... at City of Hope's Center for Gene Therapy to evaluate this new therapy in efficacy and ...
- Maryland Medical Company Claims To Have Cure For HIV, AIDSon November 8, 2019 at 1:14 pm
A Maryland medical company has submitted an application to the U.S Food and Drug Administration for a gene therapy it says will eliminate HIV. Katie Johnston reports.
- A Phase I Study of Chemotherapy and Stem Cell Gene Therapy for People with HIV Who Developed Lymphomaon September 28, 2019 at 6:04 am
A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells (AMC 097) This study is for people who are HIV-positive, have lymphoma that persists ...
via Google News and Bing News